Brand against brand · semaglutide and orforglipron

Wegovy vs Foundayo

From the two FDA labels, read Published by PepVault

Wegovy is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Foundayo is orforglipron, a GLP-1 receptor agonist, from Eli Lilly.

FDA approved Wegovy for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Foundayo is approved for weight loss and keeping it off, in adults with obesity or with overweight and a weight-related condition.

Label against label

Wegovy and Foundayo, from their FDA labels and Drugs@FDA
ComparedWegovyFoundayo
Active ingredientsemaglutideorforglipron
ClassGLP-1 receptor agonistGLP-1 receptor agonist
MakerNovo NordiskEli Lilly
Approved forWeight reduction; heart risk with obesity; MASH (injection)Weight reduction
FormsSingle-dose pen; Single-dose syringe; FlexTouch pen; TabletTablet
How oftenonce a week or once a dayonce a day
Starting dose0.25 mg a week (injection); 1.5 mg a day (tablets)0.8 mg a day
Top dose on the label7.2 mg a week (injection); 25 mg a day (tablets)17.2 mg a day
Most reported side effectNausea, 44% on 2.4 mg (placebo 16%)Nausea, 35% on 17.2 mg (placebo 10%)
Boxed warning“RISK OF THYROID C-CELL TUMORS”“RISK OF THYROID C-CELL TUMORS”
First approved20212026

Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.

The two dosing schedules

This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.

Wegovy injection, once a week

0.25 mg0.5 mg1 mg1.7 mg2.4 mg7.2 mgif needed
Wegovy’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.

Wegovy tablets, once a day

1.5 mg4 mg9 mg25 mg
Wegovy’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.

Foundayo, once a day

0.8 mg2.5 mg5.5 mg9 mgif needed14.5 mgif needed17.2 mgif needed
Foundayo’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.
A smiling woman in a dark training top in her kitchen, holding a glass of water

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

A missed dose, on each label

  • Wegovy: For a missed injection, the label looks at the next scheduled dose: more than 2 days away, take the missed one as soon as possible; less than 2 days away, skip it. Missing 2 or more weeks in a row means starting the climb again from a lower dose.
  • Foundayo: A missed Foundayo tablet is taken as soon as it’s remembered, without doubling the next one.

The trial evidence

Questions

What is the difference between Wegovy and Foundayo?

Wegovy is semaglutide, a GLP-1 receptor agonist; Foundayo is orforglipron, a GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.

What are Wegovy and Foundayo approved for?

Wegovy is approved for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Foundayo is approved for weight loss and keeping it off, in adults with obesity or with overweight and a weight-related condition.

How often are Wegovy and Foundayo taken?

Wegovy is taken once a week or once a day, as an injection or a tablet; Foundayo once a day, as a tablet.

What are the dose ranges of Wegovy and Foundayo?

On their labels, Wegovy runs 0.25 mg to 7.2 mg once a week or 1.5 mg to 25 mg once a day, and Foundayo 0.8 mg to 17.2 mg once a day. A prescriber sets the actual dose.

What is the most common side effect of Wegovy and Foundayo?

On Wegovy’s label: nausea, 44% on 2.4 mg (placebo 16%). On Foundayo’s: nausea, 35% on 17.2 mg (placebo 10%).

Sources

PepVault is not affiliated with Novo Nordisk. Wegovy is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Foundayo is a trademark of its owner.

PepVault for iPhone

Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo